Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.4 GBX
3.82%
Updated:
May 3, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
-1
Current
-36.5
Median
16.8
Industry
Higher
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=-1
Enterprise Value
/
2.8m
EBITDA
-2.8m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| UK |
|
Fusion Antibodies PLC
LSE:FAB
|
3.2m GBP | -1 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
220.9B USD | 22.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
182.8B USD | 16.5 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.5B CHF | 19.5 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.2T KRW | 33.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD | 16.3 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 26.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.9B USD | 23.8 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.9B USD | 32.8 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
24.9B USD | 16.5 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR | 32.1 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
-1.8
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A
You don't have any saved screeners yet
